Implication of RAF and RKIP genes in urinary bladder cancer

Pathology and Oncology Research

Volumn 17, Issue 2, 2011, Pages 181-190

  Zaravinos, Apostolos ^a   Chatziioannou, Maria ^a   Lambrou, George I ^c   Boulalas, Ioannis ^a,b   Delakas, Dimitris ^b   Spandidos, Demetrios A ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Computational analysis; Microarrays; qPCR; RAF family genes; RKIP; Transitional cell carcinoma of the urinary bladder

Indexed keywords

ANTINEOPLASTIC AGENT; MESSENGER RNA;

A RAF GENE; ADULT; AGED; ARTICLE; B RAF GENE; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTECTOMY; FEMALE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC CORRELATION; HUMAN; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; ONCOGENE; POLYMERASE CHAIN REACTION; RAF 1 GENE; RKIP GENE; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; NEOPLASM STAGING; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; RAF KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; URINARY BLADDER NEOPLASMS;

EID: 80051668470     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-010-9295-1     Document Type: Article

References (45)

1. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics. CA Cancer J Clin 58:71-96
2. Lopez-Beltran A, Montironi R (2004) Non-invasive urothelial neoplasms: according to the most recent WHO classification. Eur Urol 46:170-176 (Pubitemid 38902731)
3. O'Neill E, Kolch W (2004) Conferring specificity on the ubiquitous Raf/MEK signalling pathway. Br J Cancer 90:283-288 (Pubitemid 38250615)
4. Avruch J, Khokhlatchev A, Kyriakis JM et al (2001) Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res 56:127-155
5. Kolch W (2000) Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 351(Pt 2):289-305
6. Storm SM, Cleveland JL, Rapp UR (1990) Expression of raf family proto-oncogenes in normal mouse tissues. Oncogene 5:345-351
7. Barnier JV, Papin C, Eychène A, Lecoq O, Calothy G (1995) The mouse B-raf gene encodes multiple protein isoforms with tissuespecific expression. J Biol Chem 270:23381-23389
8. Luckett JC, Hüser MB, Giagtzoglou N, Brown JE, Pritchard CA (2000) Expression of the A-raf proto-oncogene in the normal adult and embryonic mouse. Cell Growth Differ 11:163-171 (Pubitemid 30185584)
9. Simister PC, Banfield MJ, Brady RL (2002) The crystal structure of PEBP-2, a homologue of the PEBP/RKIP family. Acta Crystallogr D Biol Crystallogr 58:1077-1080 (Pubitemid 34653050)
10. Odabaei G, Chatterjee D, Jazirehi AR, Goodglick L, Yeung K, Bonavida B (2004) Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv Cancer Res 91:169-200 (Pubitemid 39140959)
11. Yeung K, Seitz T, Li S et al (1999) Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 401:173-177 (Pubitemid 29436321)
12. Park S, Yeung ML, Beach S, Shields JM, Yeung KC (2005) RKIP downregulates B-Raf kinase activity in melanoma cancer cells. Oncogene 24:3535-3540 (Pubitemid 40756254)
13. Fu Z, Smith PC, Zhang L et al (2003) Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst 95:878-889 (Pubitemid 36833879)
14. Schuierer MM, Bataille F, Hagan S, Kolch W, Bosserhoff AK (2004) Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res 64:5186-5192 (Pubitemid 39006537)
15. Van Gelder RN, von Zastrow ME, Yool A, Dement WC, Barchas JD, Eberwine JH (1990) Amplified synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci USA 87:1663-1667
16. Diez Alvarez DR, Dopazo A (2007) Codelink: an R package for analysis of GE healthcare gene expression bioarrays. Bioinformatics 23:1168-1169 (Pubitemid 47050572)
17. Altman NS, Hua J (2006) Extending the loop design for two-channel microarray experiments. Genet Res 88:153-163
18. Sturn A, Quackenbush J, Trajanoski Z (2002) Genesis: cluster analysis of microarray data. Bioinformatics 18:207-208 (Pubitemid 34145055)
19. Boulalas I, Zaravinos A, Karyotis I, Delakas D, Spandidos DA (2009) Activation of RAS family genes in urothelial carcinoma. J Urol 181:2312-2319
20. Dyrskjøt L, Kruhøffer M, Thykjaer T et al (2004) Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 64:4040-4048 (Pubitemid 38697320)
21. Mengual L, Burset M, Ars E et al (2009) DNA microarray expression profiling of bladder cancer allows identification of noninvasive diagnostic markers. J Urol 182:741-748
22. Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-954 (Pubitemid 34716871)
23. Zlobec I, Kovac M, Erzberger P et al (2010) Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer. Int J Cancer Feb. 16, 2010
24. Zlobec I, Bihl MP, Schwarb H, Terracciano L, Lugli A (2009) Clinicopathological and protein characterization of BRAF-and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer Nov. 11, 2009
25. Libra M, Malaponte G, Navolanic PM et al (2005) Analysis of BRAF mutation in primary and metastatic melanoma. Cell Cycle 10:1382-1384 (Pubitemid 41437127)
26. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE (2010) Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 16:790-799
27. Boulalas I, Zaravinos A, Delakas D, Spandidos DA (2009) Mutational analysis of the BRAF gene in transitional cell carcinoma of the bladder. Int J Biol Markers 24:17-21
28. Zaravinos A, Kanellou P, Baritaki S, Bonavida B, Spandidos DA (2009) BRAF and RKIP are significantly decreased in cutaneous squamous cell carcinoma. Cell Cycle 8:1402-1408
29. Zaravinos A, Bizakis J, Spandidos DA (2008) RKIP and BRAF aberrations in human nasal polyps and the adjacent turbinate mucosae. Cancer Lett 264:288-298
30. Gattenlöhner S, Etschmann B, Riedmiller H, Müller-Hermelink HK (2009) Lack of KRAS and BRAF mutation in renal cell carcinoma. Eur Urol 55:1490-1491
31. Karlou M, Saetta AA, Korkolopoulou P et al (2009) Activation of extracellular regulated kinases (ERK1/2) predicts poor prognosis in urothelial bladder carcinoma and is not associated with B-Raf gene mutations. Pathology 41:327-334
32. Mhawech-Fauceglia P, Fischer G, Beck A, Cheney RT, Herrmann FR (2006) Raf1, Aurora-A/STK15 and E-cadherin biomarkers expression in patients with pTa/pT1 urothelial bladder carcinoma; a retrospective TMA study of 246 patients with long-term follow-up. Eur J Surg Oncol 32:439-444
33. McPhillips F, Mullen P, MacLeod KG et al (2006) Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells. Carcinogenesis 27:729-739
34. Simon R, Richter J, Wagner U et al (2001) High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res 61:4514-4519 (Pubitemid 32685782)
35. O'Neill E, Rushworth L, Baccarini M, Kolch W (2004) Role of the kinase MST2 in suppression of apoptosis by the protooncogene product Raf-1. Science 306:2267-2270 (Pubitemid 40024466)
36. Ehrenreiter K, Piazzolla D, Velamoor V et al (2005) Raf-1 regulates Rho signaling and cell migration. J Cell Biol 168:955-964 (Pubitemid 40397009)
37. Wan PT, Garnett MJ, Roe SM, Lee S et al (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855-867 (Pubitemid 38410730)
38. Keller ET, Fu Z, Yeung K, Brennan M (2004) Raf kinase inhibitor protein: a prostate cancer metastasis suppressor gene. Cancer Lett 207:131-137 (Pubitemid 38457033)
39. Fu Z, Kitagawa Y, Shen R et al (2006) Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate 66:248-256 (Pubitemid 43191224)
40. Blaveri E, Brewer JL, Roydasgupta R et al (2005) Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res 11:7012-7022 (Pubitemid 41428761)
41. Keller ET, Fu Z, Brennan M (2005) The biology of a prostate cancer metastasis suppressor protein: Raf kinase inhibitor protein. J Cell Biochem 94:273-278 (Pubitemid 41420306)
42. Woods Ignatoski KM, Grewal NK, Markwart SM et al (2008) Loss of Raf kinase inhibitory protein induces radioresistance in prostate cancer. Int J Radiat Oncol Biol Phys 72:153-160
43. Li HZ, Wang Y, Gao Y et al (2008) Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer. Mol Cancer Res 6:917-928
44. Lou TF, Gray CW, Gray DM (2003) The reduction of Raf-1 protein by phosphorothioate ODNs and siRNAs targeted to the same two mRNA sequences. Oligonucleotides 13:313-324 (Pubitemid 38404816)
45. Chatterjee D, Bai Y, Wang Z et al (2004) RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem 279:17515-17523 (Pubitemid 38560515)